Biomedical Genomics and Oncogenetics Research Laboratory, Faculty of Sciences and Techniques of Tangier, University Abdelmalek Essaâdi, 90000, Tangier, Morocco.
Molecular Biology Department, ANOUAL Laboratory, Casablanca, Morocco.
BMC Cancer. 2020 Aug 10;20(1):747. doi: 10.1186/s12885-020-07250-0.
Hereditary breast and ovarian cancer (HBOC) is an autosomal dominant inherited cancer susceptibility disorder. Both BRCA1 and BRCA2 genes are considered as high penetrance genes of this syndrome. The identification of BRCA1/2 genetic alterations before cancer development, grant patients the chance to benefit from various medical cancer prevention approaches. Therefore, the appearance of recent advanced technologies in molecular analysis such as next generation sequencing has simplified full BRCA1/2 analysis. Many attempts took place in hope of understanding the molecular germline spectrum of these two genes in Moroccan HBOC patients. However, most of the past projects focused only on young breast cancer cases, lacked ovarian cancer cases in their cohort and only a limited number of these studies were able to analyze the entire exons or copy number variations for both genes. In attempt of gaining more information regarding the molecular profile of BRCA1/2 in HBOC, we conducted a study in which we analyze their molecular profile on selected Moroccan patients suspected of having HBOC syndrome.
In this study we obtained blood samples from 64 selected Moroccan patients, who suffered from Breast and/or ovarian cancer and had a strong family history for cancer. To analyze BRCA1/2 punctual variants and copy number variations, we used the Ion Personal Genome Machine (PGM) and Oncomine BRCA1/2 research assay panel. Afterward, we correlated the molecular results with the clinic-pathologic data using IBM SPSS Statistics ver 2.
From the 64 selected cases, Forty-six had breast cancer, fifteen had ovarian cancer and three had both breast and ovarian cancer. The molecular analysis revealed that 18 patients from the 64 harbored a pathogenic variant (28%). Twelve had six different BRCA1 pathogenic variants and six had six different BRCA2 pathogenic variants. In this study, we report four pathogenic variants that to the best of our knowledge has never been reported in the Moroccan population before. Regarding copy number variation analysis, No CNV was detected in both genes for all the 64 successfully sequenced and analyzed patients in our cohort.
Work like the present has an important implication on public health and science. It is critical that molecular profiling studies are performed on underserved and understudied population like Morocco.
遗传性乳腺癌和卵巢癌(HBOC)是一种常染色体显性遗传的癌症易感性疾病。BRCA1 和 BRCA2 基因被认为是该综合征的高外显率基因。在癌症发生之前确定 BRCA1/2 基因的改变,使患者有机会受益于各种医学癌症预防方法。因此,新一代测序等分子分析的新技术的出现简化了对 BRCA1/2 的全面分析。许多尝试都在努力了解摩洛哥 HBOC 患者这两个基因的种系分子谱。然而,过去的大多数项目都只关注年轻的乳腺癌病例,在其队列中缺乏卵巢癌病例,而且只有少数这些研究能够分析这两个基因的整个外显子或拷贝数变异。为了更深入地了解 HBOC 中 BRCA1/2 的分子特征,我们进行了一项研究,对 64 名疑似患有 HBOC 综合征的摩洛哥患者进行了分子特征分析。
在这项研究中,我们从 64 名患有乳腺癌和/或卵巢癌且有强烈癌症家族史的摩洛哥患者中获得了血液样本。为了分析 BRCA1/2 的点突变和拷贝数变异,我们使用了 Ion Personal Genome Machine (PGM) 和 Oncomine BRCA1/2 研究检测面板。之后,我们使用 IBM SPSS Statistics ver 2 将分子结果与临床病理数据相关联。
从 64 名选定的病例中,46 名患有乳腺癌,15 名患有卵巢癌,3 名同时患有乳腺癌和卵巢癌。分子分析显示,64 名患者中有 18 名携带致病性变异(28%)。12 名患者携带 6 种不同的 BRCA1 致病性变异,6 名患者携带 6 种不同的 BRCA2 致病性变异。在这项研究中,我们报告了 4 种致病性变异,据我们所知,这些变异在摩洛哥人群中以前从未报道过。关于拷贝数变异分析,我们在所有成功测序和分析的 64 名患者的两个基因中都没有检测到 CNV。
像这样的工作对公共卫生和科学具有重要意义。对像摩洛哥这样的服务不足和研究不足的人群进行分子分析研究至关重要。